Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2019 Jun 13. pii: haematol.2019.224121. doi: 10.3324/haematol.2019.224121. [Epub ahead of print]

2.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1602268. [Epub ahead of print]

PMID:
31014142
3.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.

PMID:
30575108
4.

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA.

Br J Haematol. 2018 Nov;183(3):421-427. doi: 10.1111/bjh.15545. Epub 2018 Aug 16.

PMID:
30117139
5.

Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.

Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD.

Haematologica. 2018 Jun;103(6):e237-e240. doi: 10.3324/haematol.2017.183194. Epub 2018 Feb 1. No abstract available.

6.

Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.

Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Am J Hematol. 2017 Dec;92(12):1362-1369. doi: 10.1002/ajh.24915. Epub 2017 Oct 19.

7.

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE.

Leuk Lymphoma. 2017 Jul;58(7):1630-1639. doi: 10.1080/10428194.2016.1257795. Epub 2016 Nov 25.

PMID:
27885886
8.

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Leuk Lymphoma. 2017 Jun;58(6):1376-1383. doi: 10.1080/10428194.2016.1251592. Epub 2016 Nov 8.

9.

Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.

Nabhan C, Chaffee KG, Slager SL, Galanina N, Achenbach SJ, Schwager SM, Kay NE, Shanafelt TD.

Am J Hematol. 2016 Jul;91(7):677-80. doi: 10.1002/ajh.24374. Epub 2016 Apr 24.

10.

Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.

Solomon BM, Chaffee KG, Moreira J, Schwager SM, Cerhan JR, Call TG, Kay NE, Slager SL, Shanafelt TD.

Leukemia. 2016 Feb;30(2):331-6. doi: 10.1038/leu.2015.235. Epub 2015 Aug 27.

11.

Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD.

Haematologica. 2015 Sep;100(9):1180-8. doi: 10.3324/haematol.2015.128793. Epub 2015 Jun 18.

12.

The efficacy of ibrutinib in the treatment of Richter syndrome.

Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, Nowakowski GS, Bowen D, Conte M, Schwager SM, Slager SL, Kay NE, Hanson CA, Parikh SA.

Blood. 2015 Mar 5;125(10):1676-8. doi: 10.1182/blood-2014-12-610782. No abstract available.

13.

Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD.

Am J Hematol. 2015 Apr;90(4):334-8. doi: 10.1002/ajh.23939. Epub 2015 Jan 30.

14.

Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication.

Bowen DA, Rabe KG, Schwager SM, Slager SL, Call TG, Viswanatha DS, Zent CS.

Leuk Lymphoma. 2015 Feb;56(2):311-4. doi: 10.3109/10428194.2014.914202. Epub 2014 Jun 25.

PMID:
24738974
15.

Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, Call TG, Viswanatha DS, Zent CS.

Leuk Lymphoma. 2014 Sep;55(9):2079-84. doi: 10.3109/10428194.2013.869801. Epub 2014 Feb 17.

16.

Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia.

Mansfield AS, Rabe KG, Slager SL, Schwager SM, Call TG, Brewer JD, Shanafelt TD.

J Oncol Pract. 2014 Jan;10(1):e1-4. doi: 10.1200/JOP.2013.000921. Epub 2013 Aug 27.

17.

Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.

Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL, Shanafelt TD.

Haematologica. 2014 Jan;99(1):140-7. doi: 10.3324/haematol.2013.086066. Epub 2013 Aug 2.

18.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.

Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD.

Br J Haematol. 2013 Sep;162(6):774-82. doi: 10.1111/bjh.12458. Epub 2013 Jul 11.

19.

Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.

Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, Leis JF, Jelinek DF, Schwager SM, Bowen DA, Hanson CA, Slager SL, Shanafelt TD.

Leukemia. 2013 Jan;27(1):136-41. doi: 10.1038/leu.2012.187. Epub 2012 Jul 11.

PMID:
22781591
20.

Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG.

Cancer. 2012 Apr 1;118(7):1827-37. doi: 10.1002/cncr.26474. Epub 2011 Aug 26.

21.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, Leis JF, Jelinek DF, Slager SL, Hanson CA.

Leukemia. 2012 Feb;26(2):373-6. doi: 10.1038/leu.2011.211. Epub 2011 Aug 12. No abstract available.

PMID:
21836611
22.

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A.

Haematologica. 2010 Oct;95(10):1788-91. doi: 10.3324/haematol.2010.025064.

23.

Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.

Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE.

Blood. 2010 Oct 21;116(16):2984-93. doi: 10.1182/blood-2010-02-269894. Epub 2010 Jul 6.

24.

Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.

Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, Schwager SM, Bowen DA, Slager SL, Hanson CA, Call TG.

Cancer. 2010 Oct 15;116(20):4777-87. doi: 10.1002/cncr.25292.

25.

CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S35-41. doi: 10.1002/cyto.b.20546.

26.

Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.

Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, Bowen DA, Schwager SM, Nowakowski GS.

Leuk Lymphoma. 2010 Jul;51(7):1233-40. doi: 10.3109/10428194.2010.486877.

27.

Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.

Bowen DA, Call TG, Shanafelt TD, Kay NE, Schwager SM, Reinalda MS, Rabe KG, Slager SL, Zent CS.

Leuk Lymphoma. 2010 Apr;51(4):620-7. doi: 10.3109/10428191003682767.

28.

Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.

Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F.

Am J Hematol. 2010 Jan;85(1):14-7. doi: 10.1002/ajh.21574.

29.

Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.

Vaidya R, Siragusa S, Huang J, Schwager SM, Hanson CA, Hussein K, Pardanani A, Tefferi A.

Mayo Clin Proc. 2009 Dec;84(12):1114-9. doi: 10.4065/mcp.2009.0543.

30.

A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia.

Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE.

Br J Haematol. 2010 Feb;148(4):544-50. doi: 10.1111/j.1365-2141.2009.07982.x. Epub 2009 Nov 6.

31.

Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.

Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL.

Leuk Lymphoma. 2009 Aug;50(8):1261-8.

32.

Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.

Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A.

Cancer. 2009 Dec 15;115(24):5740-5. doi: 10.1002/cncr.24664.

33.

Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.

Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE.

Br J Haematol. 2009 Nov;147(4):471-83. doi: 10.1111/j.1365-2141.2009.07868.x. Epub 2009 Sep 8.

34.

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.

Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A.

Mayo Clin Proc. 2008 Apr;83(4):457-9. doi: 10.4065/83.4.457.

PMID:
18380991
35.

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL.

Br J Haematol. 2008 May;141(5):615-21. doi: 10.1111/j.1365-2141.2008.07086.x. Epub 2008 Mar 27.

36.

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.

Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD.

Leuk Lymphoma. 2007 Dec;48(12):2412-7.

PMID:
18067017
37.

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.

Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A.

Leuk Res. 2007 Nov;31(11):1503-9. Epub 2007 Mar 29.

PMID:
17397921
38.

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.

Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A.

Cancer. 2006 Jun 1;106(11):2406-11.

39.

Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A.

Cancer. 2006 May 1;106(9):1985-9.

40.

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A.

Mayo Clin Proc. 2006 Feb;81(2):159-66.

PMID:
16471068
41.

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.

Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A.

Cancer. 2006 Feb 1;106(3):623-30.

42.

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG.

Cancer. 2006 Feb 1;106(3):631-5.

43.

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D.

Br J Haematol. 2005 Nov;131(3):320-8.

PMID:
16225651
44.

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.

Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A.

Br J Haematol. 2005 Oct;131(2):208-13.

PMID:
16197451
45.

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.

Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG.

Br J Haematol. 2005 Oct;131(2):166-71.

PMID:
16197445

Supplemental Content

Loading ...
Support Center